Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
FR00140048X2
Tue, 23.07.2024
Ikonisys SA
Company Name:
Ikonisys SA
ISIN:
FR00140048X2
Reason for the research:
Update Report
Recommendation:
Buy
from:
23.07.2024
Target price:
EUR 5.50 (previously: EUR 6.30)
Target price on sight of:
36 months
Last rating change:
-
Analyst:
Peter Thilo Hasler, CEFA
The figures published last week for the past financial year 2023 wer [ … ]
Tue, 06.02.2024
Ikonisys SA
Creating a leading player in cancer diagnostics
Only weeks after Ikonisys entered a strategic partnership with Biocare
Medical, the company made the next strategic step in business development
by announcing the takeover of Hospitex, an Italian-based cytology company
specialising in oncological diagnostics. According to the company, Hospite [ … ]
Wed, 01.11.2023
Ikonisys SA
Strategic alliance with Biocare Medical is a game changer
Ikonisys announced that it has entered a strategic partnership with Biocare
Medical which will take advantage of each firm’s respective strengths to
drive and deepen their leading-edge technology positions. Ikonisys, in
addition, will substantially expand its global footprint [ … ]
Mon, 31.07.2023
Ikonisys SA
Second sale of the high-volume Ikoniscope20max
With another sale completed of the Ikonicope20max, the high-end,
high-volume configuration of the Ikoniscope20 for high-throughput
laboratories, we believe Ikonisys is on track to expand its global reach
and to meet our long-term financial targets. We are confirming our Buy
rating for the shar [ … ]
Mon, 31.07.2023
Ikonisys SA
Second sale of the high-volume Ikoniscope20max
With another sale completed of the Ikonicope20max, the high-end,
high-volume configuration of the Ikoniscope20 for high-throughput
laboratories, we believe Ikonisys is on track to expand its global reach
and to meet our long-term financial targets. We are confirming our Buy
rating for the shar [ … ]
Mon, 08.05.2023
Ikonisys SA
Accelerated business expected
With a strong product pipeline in Circulating Tumor Cells (CTC) based early
cancer detection and treatment monitoring and the integration of AI into
the existing platform, as well as secure funding from Atlas Capital
Markets, we see Ikonisys to be well on track to expand its global reach and
to meet our long-te [ … ]
Mon, 08.05.2023
Ikonisys SA
Accelerated business expected
With a strong product pipeline in Circulating Tumor Cells (CTC) based early
cancer detection and treatment monitoring and the integration of AI into
the existing platform, as well as secure funding from Atlas Capital
Markets, we see Ikonisys to be well on track to expand its global reach and
to meet our long-te [ … ]
Mon, 31.10.2022
Ikonisys SA
H1/2022 in-line with our expectations
Following the publication of the H1/2022-report, we are slightly adjusting
our revenue and earnings forecasts. After refreshing the valuation-relevant
risk parameters, we calculate an unchanged target price of EUR 6.70 from
our three-stage DCF entity model (base case scenario). In a Monte Carlo
analysis [ … ]
Mon, 31.10.2022
Ikonisys SA
H1/2022 in-line with our expectations
Following the publication of the H1/2022-report, we are slightly adjusting
our revenue and earnings forecasts. After refreshing the valuation-relevant
risk parameters, we calculate an unchanged target price of EUR 6.70 from
our three-stage DCF entity model (base case scenario). In a Monte Carlo
analysis [ … ]
Wed, 12.10.2022
Ikonisys SA
Mandatory convertible bond
The issuance of a mandatory convertible bond with warrants attached
provides Ikonisys with the liquidity needed for the global commercial
roll-out strategy of the Ikoniscope20 and the further development of the
microscopy platform into a state-of-the-art Artificial Intelligence system,
in our view. In addition, Ik [ … ]